^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | voruciclib (ME-522) (CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1962 - Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models
Published date:
03/10/2021
Excerpt:
The ability of voruciclib to inhibit tumor growth in vivo was also tested in murine xenograft models. KRAS mutant human cancer cells HCT-116 (CRC, KRAS G13D), SW-480 (CRC, KRAS G12V), and H-460 (NSCLC, KRAS Q61H) were injected subcutaneously into SCID mice. Once tumors reached 5-10 mm in diameter, voruciclib or vehicle were administered orally at 50, 100, or 200 mg/kg OD for 11-14 days. Tumors were measured every 2-3 days, and growth inhibition relative to control was calculated. Significant tumor growth inhibition (>50%) was observed at all doses of voruciclib tested.
